

**Consideration of New 22 Tex. Admin. Code §228.2, relating to *Prescription Monitoring Program***

**Background:** House Bill (HB) 2561, which became effective on September 1, 2017, requires all practitioners to access the Prescription Monitoring Program (PMP) prior to prescribing or dispensing opioids, benzodiazepines, barbiturates, or carisoprodol. The bill further authorizes, but does not require, practitioners to access the PMP prior to prescribing or dispensing any controlled substance. The proposed rule, attached as Attachment "A", implements these statutory requirements and provides guidance to Board regulated practitioners who prescribe these medications.

**Board Action:** Move to approve new 22 Tex. Admin. Code §228.2, relating to *Prescription Monitoring Program*, with authority for the General Counsel to make editorial changes as necessary to clarify rule and Board intent and to comply with the formatting requirements of the *Texas Register*. If no negative comments and no request for a public hearing are received, move to adopt new 22 Tex. Admin. Code §228.2, relating to *Prescription Monitoring Program*, as proposed.

Attachment "A"

§228.2. Prescription Monitoring Program (PMP).

(a) APRNs should access and review the prescription monitoring program (PMP) authorized by Chapter 481, Health and Safety Code, prior to prescribing any controlled substance for patients being treated for pain.

(b) APRNs must access and review the PMP before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol unless:

(1) the patient has been diagnosed with cancer or the patient is receiving hospice care; and

(2) the APRN clearly notes in the prescription record that the patient was diagnosed with cancer or is receiving hospice care, as applicable.

(c) Documentation that the review of the PMP occurred and rationale for prescribing a controlled substance must be included in the medical record.